NCT06188026View on ClinicalTrials.gov

A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Healthy Volunteers (Non-alcoholic Steatohepatitis)
Interventions
DRUG

NNC0194-0499

Once a week for 5 weeks as an injection in dose of 30 mg. The injection will be given under the skin

DRUG

ethinylestradiol/levonorgestrel

Oral contraceptive is taken as tablet daily composed of 30 μg ethinylestradiol and 150 μg levonorgestrel.

Trial Locations (1)

8010

Medical University of Graz, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY